NONOF News and Press, Novo-Nordisk A/S From 12/15/23

2023-12-15 11:34:09 ET Summary Celsius Holdings is a company that specializes in fitness drinks and is tapping into the health-conscious trend. The company's latest quarterly report shows strong financial performance, with a significant increase in revenue and net income. The ...

2023-12-14 06:57:08 ET More on Alkermes, Novo Nordisk: Novo Nordisk: Latest Insights Confirm Exceptionally Bullish Opportunity Novo Nordisk: Plenty More Room To Run Despite Its Hefty Valuation Alkermes: A Complicated Story Right Now Lybalvi: Wei...

2023-12-13 13:37:28 ET More on AmWell, Teladoc, etc. Teladoc: High Stock Compensation Is An Issue Teladoc: No Floor Yet Teladoc's Valuation Proposition: 7x EBITDA In 2024, Not So Bad Global telemedicine market to hit $450B in 2032: report American Wel...

2023-12-12 11:51:20 ET More on Amgen Amgen Inc. (AMGN) Presents at 6th Annual Evercore ISI HealthCONx Conference (Transcript) AbbVie Vs. Amgen: How Peter Lynch Picks Dividend Stocks Amgen: Buy In Stable Fundamental And Technical Price Growth Amazon Web Servic...

2023-12-12 11:07:43 ET Summary Investors should consider tax-loss selling before December ends to offset capital gains. Two characteristics to consider for selling stocks are stocks bought at a higher price and broken companies with weak long-term prospects. Stock grades, sent...

2023-12-11 11:52:10 ET More on Eli Lilly Bubble Warning: Unrealistic Growth Priced In And Multiple Risk Factors For Eli Lilly Eli Lilly and Company (LLY) Presents at 6th Evercore ISI HealthCONx Conference (Transcript) Eli Lilly: Perfectly Priced Healthcare Giant ...

2023-12-06 05:38:29 ET Summary Positive results were achieved from the 48-week phase 2 MOMENTUM study using pemvidutide for the treatment of patients with obesity. The highest dose of 2.4 mg of pemvidutide achieved 15.6% weight loss for obese patients. Altimmune has two other ...

2023-12-05 01:41:55 ET Summary Mondelez International's shares are attractive compared to peers, with potential annual returns of approximately 13%. The company's exposure to faster-growing verticals, regional diversification, and strong management make it a compelling investment....

2023-12-03 04:00:32 ET Summary In 2023, AI and the Magnificent 7 took the lead, leaving non-tech blue chip companies trailing behind in the rearview mirror. Abbott Laboratories had a difficult last three years, with its stock price trading sideways as sales driven by COVID-19 plum...

2023-12-01 12:50:00 ET More on Pfizer, Rhythm Pharma etc. Pfizer Inc. (PFE) 6th Annual Evercore ISI HealthCONx Conference (Transcript) Pfizer Is A Fantastic Buy And So Are These 9%-Yielding Blue Chips Rhythm Pharmaceuticals: Major Catalysts Due For Weight Loss Specia...